Company intelligence / Profile preview

LAAx

Ownership: Private
Development stage: Other

Overview

LAAx developed the TigerPaw II System, an implantable mechanical occlusion device designed to safely and effectively close the left atrial appendage during open chest cardiac surgery. The TigerPaw II features a soft silicone fastener that conforms to tissue anatomy, aiming to reduce risks such as tissue damage and bleeding compared to other closure methods. The product received regulatory clearance in both the United States and European Union and was commercially launched in those regions in 2013.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on LAAx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAAx.

Explore the full profile